Okayama University Researchers Successfully Implant Retinal Prosthesis in Monkey Eyes

June 29, 2018: By Jon Swedien

Researchers at Okayama University surgically implanted a retinal prosthesis in monkeys suffering from macular degeneration, the university announced June 28.

The scientists published their results in the journal Artificial Organs.

The university said the study demonstrated the implantation’s surgical feasibility. They also said it marks an important step toward the development of a treatment for patients with macular degeneration and retinitis pigmentosa.

The subretinal implant, known as Okayama University-type retinal prosthesis (OUReP), is made of a material based on photoelectric dye molecules, capable of converting light into electric potentials, mimicking phototransduction in mammalian eyes.

Monkeys were used because their retinas have a macular structure similar to human retinas. Also, monkey studies are a necessary intermediate step required by Japan’s Pharmaceuticals and Medical Devices Agency toward the development of implants for human eyes, the university said.

All monkeys involved in the experiments were healthy during the observation period, the university said. The researchers checked that no monkeys developed retinal toxicity or inflammatory cells.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023